Description
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence. Participants will receive Atezolizumab + Bevacizumab until disease recurrence or unacceptable toxicity. Drug: Atezolizumab Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle. Other Name: Tecentriq Drug: Bevacizumab Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle. Other Name: Avastin
